Keppra Drug Interactions and Accumulation in the Elderly
Keppra (levetiracetam) has minimal clinically significant drug interactions and does accumulate in elderly patients primarily due to reduced renal clearance, requiring dose adjustment in this population.
Drug Interactions
Minimal Interaction Profile
Levetiracetam has an exceptionally favorable drug interaction profile compared to traditional antiepileptic drugs. The drug is neither an inhibitor nor substrate of hepatic cytochrome P450 enzymes, epoxide hydrolase, or UDP-glucuronidation enzymes 1. This means it does not interfere with the metabolism of most other medications.
Specific Drug Interactions Studied
The FDA label and clinical studies confirm no clinically significant interactions with the following medications 1:
- Other antiepileptic drugs: No effect on phenytoin, valproate, carbamazepine, gabapentin, lamotrigine, phenobarbital, or primidone levels
- Oral contraceptives: No impact on ethinyl estradiol/levonorgestrel efficacy or hormone levels
- Warfarin: No effect on R or S warfarin pharmacokinetics or prothrombin time
- Digoxin: No pharmacokinetic or pharmacodynamic interactions
- Valproic acid: Specifically studied with no mutual interaction 2
Notable Exception: Probenecid
The only documented interaction is with probenecid, which doubles the concentration of levetiracetam's inactive metabolite (ucb L057) by blocking tubular secretion, though this has no clinical significance 1.
Enzyme-Inducing AEDs in Pediatrics
In pediatric patients, co-administration with enzyme-inducing antiepileptic drugs increases levetiracetam clearance by approximately 22%, but dose adjustment is not recommended 1.
Protein Binding
Levetiracetam is less than 10% protein-bound, making drug-drug interactions through protein binding displacement essentially impossible 1.
Accumulation in the Elderly
Yes, Levetiracetam Accumulates
The plasma half-life of levetiracetam increases from 6-8 hours in adults to 10-11 hours in elderly patients 1, 3. This accumulation occurs because:
- Renal clearance decreases with age: Levetiracetam is 66% renally excreted unchanged 1
- Clearance is reduced by almost half in patients over 65 compared to younger adults 4
- Elimination correlates directly with creatinine clearance, which declines with aging 1
Clinical Implications
The FDA label explicitly states: "Plasma half-life of levetiracetam across studies is approximately 6-8 hours. It is increased in the elderly (primarily due to impaired renal clearance)" 1.
Dose adjustment is necessary in elderly patients with moderate to severe renal impairment 3. The mechanism is straightforward: levetiracetam undergoes glomerular filtration with partial tubular reabsorption, and age-related decline in kidney function directly reduces drug clearance 1.
Therapeutic Drug Monitoring Considerations
While routine therapeutic drug monitoring is generally unnecessary for levetiracetam, it may be beneficial in elderly patients to maintain an individual therapeutic range given the altered pharmacokinetics 4. This is particularly important because elderly patients often have multiple comorbidities affecting renal function.
Advantages in Elderly Patients
Despite accumulation concerns, levetiracetam is actually preferred in elderly patients with hepatic disease because it is not metabolized by the liver 5. The drug's lack of interactions with other medications makes it particularly suitable for elderly patients on polypharmacy 5, 6.
Common Pitfalls
- Do not assume standard adult dosing is appropriate: Always assess renal function in elderly patients before dosing
- Monitor for CNS effects: The increased half-life may lead to enhanced sedation or behavioral changes
- Cardiac considerations: Unlike phenytoin, carbamazepine, and lamotrigine, levetiracetam does not cause cardiac conduction abnormalities, making it safer in elderly patients with cardiac disease 5